Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.59 |
| ▸ | NQO2 | P16083 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.55 |
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459991 | 1.00 | PTGS1 (0.59) | PTGS1NQO2PTGS2NFE2L2APP | |
| SCHEMBL6469802 | 0.85 | PPARG (0.51) | PTGS1NQO2PTGS2 | |
| SCHEMBL918394 | 0.85 | PPARG (0.51) | PTGS1NQO2PTGS2 | |
| SCHEMBL919514 | 0.83 | PPARG (0.53) | PTGS1NQO2PTGS2NFE2L2APP | |
| SCHEMBL6469970 | 0.83 | PPARG (0.53) | PTGS1NQO2PTGS2NFE2L2APP | |
| SCHEMBL6468960 | 0.82 | AHR (0.54) | PTGS1PTGS2RELA | |
| SCHEMBL918449 | 0.82 | AHR (0.54) | PTGS1PTGS2RELA | |
| SCHEMBL6468964 | 0.82 | AHR (0.54) | PTGS1PTGS2RELA | |
| SCHEMBL919014 | 0.82 | NFE2L2 (0.46) | PTGS1NQO2PTGS2NFE2L2 | |
| SCHEMBL6471008 | 0.79 | PTGS1 (0.58) | PTGS1PTGS2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | claimed |
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | PTGS1 275/4885NQO2 2538/4885PTGS2 293/4885 |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | PTGS1 430/4885NQO2 3623/4885PTGS2 512/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | PTGS1 256/4885NQO2 4022/4885PTGS2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.